Kallyope Announces Positive Results from Phase 2b Study of Elismetrep for the Acute Treatment of Migraine
Kallyope, a late-stage biotechnology company leveraging unique insights into neural signaling pathways to develop innovative therapies for migraine and metabolism, today announced positive results from a Phase 2b study...

